Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intravesical Cidofovir for Hemorrhagic Cystitis

Phase 1

Completed

Conditions: Blood And Marrow Transplantation

Interventions: Drug: Cidofovir
Drug: Probenecid

First Posted Date: 2013-03-22

Last Posted Date: 2016-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01816646

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Phase 1

Terminated

Conditions: Colorectal Carcinoma

Interventions: Drug: Metformin ER

First Posted Date: 2013-03-22

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01816659

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Procedure: Acupuncture
Behavioral: Questionnaires
Other: Hand Function and Balance Tests

First Posted Date: 2013-03-21

Last Posted Date: 2018-01-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01815346

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Not Applicable

Completed

Conditions: Cancer of Lymph Node

Interventions: Drug: Feraheme
Procedure: Magnetic Resonance Imaging (MRI)

First Posted Date: 2013-03-21

Last Posted Date: 2020-10-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01815333

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fentanyl for Breakthrough Pain in the Emergency Department

Phase 4

Terminated

Conditions: Pain

Interventions: Drug: Fentanyl Nasal Spray
Drug: Hydromorphone PCA
Other: Placebo Nasal Spray

First Posted Date: 2013-03-18

Last Posted Date: 2021-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01812759

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers

Completed

Conditions: Tobacco Use Cessation

Interventions: Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2013-03-14

Last Posted Date: 2017-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT01811628

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Other: Thoracic Reirradiation Registry

First Posted Date: 2013-03-11

Last Posted Date: 2016-08-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT01808677

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Phase 1

Terminated

Conditions: Myeloma

Interventions: Drug: Pomalidomide
Drug: Melphalan
Drug: Dexamethasone
Behavioral: Questionnaires

First Posted Date: 2013-03-08

Last Posted Date: 2016-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01807286

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: CD5789 0.01% Cream

First Posted Date: 2013-03-05

Last Posted Date: 2016-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01804335

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Metformin
Drug: Letrozole
Drug: Everolimus

First Posted Date: 2013-02-22

Last Posted Date: 2025-05-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01797523

Locations: 🇺🇸
Sacred Heart Health Systems, Pensacola, Florida, United States
🇺🇸
Memorial City Medical Center, Houston, Texas, United States
🇺🇸
MD Anderson Cooper Cancer Center, Voorhees Township, New Jersey, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy